Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


adhesion ( 53 / 29 /
8
/
16
)
Angiogenesis ( 298 / 154 /
51
/
93
)
Anoikis ( 28 / 15 /
5
/
8
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 2005 / 1016 /
634
/
355
)
Autophagy ( 476 / 239 /
109
/
128
)
beta-catenin signaling ( 75 / 38 /
14
/
23
)
cell cycle ( 260 / 136 /
45
/
79
)
cell cycle arrest ( 515 / 261 /
226
/
28
)
Cell growth ( 822 / 415 /
123
/
284
)
Chemoresistance ( 302 / 152 /
57
/
93
)
colony formation ( 541 / 276 /
71
/
194
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 65 / 33 /
23
/
9
)
EMT ( 981 / 497 /
199
/
285
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 113 / 57 /
25
/
31
)
Invasion ( 3977 / 2014 /
652
/
1311
)
MET ( 18 / 10 /
8
/
)
Metastasis ( 1203 / 610 /
246
/
347
)
migration ( 3167 / 1599 /
514
/
1054
)
motility ( 215 / 110 /
34
/
71
)
NF-kB signaling ( 235 / 119 /
61
/
55
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 31 / 16 /
7
/
8
)
Paclitaxel resistance ( 69 / 35 /
13
/
21
)
Proliferation ( 4496 / 2268 /
734
/
1494
)
Radioresistance ( 145 / 74 /
27
/
44
)
Senescence ( 75 / 41 /
26
/
8
)
stemness ( 251 / 126 /
57
/
68
)
survival ( 136 / 70 /
24
/
42
)
Tamoxifen resistance ( 25 / 13 /
8
/
4
)
5fluorouracil resistance ( 126 / 72 /
23
/
31
)
AKT signaling ( 319 / 161 /
55
/
103
)
cell viability ( 322 / 165 /
40
/
117
)
cisplatin resistance ( 368 / 185 /
63
/
120
)
doxorubicin resistance ( 87 / 44 /
13
/
30
)
ERK pathway (MAPK pathway) ( 199 / 100 /
31
/
68
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 28 / 16 /
4
/
8
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 22 / 12 /
5
/
5
)
RAS signaling pathway ( 10 / 6 /
2
/
2
)
tumor growth ( 912 / 459 /
158
/
295
)
cancer progression ( 16 / 9 /
5
/
2
)
cell cycle progression ( 189 / 96 /
46
/
47
)
Lung metastasis ( 71 / 37 /
17
/
17
)
PI3K signaling ( 109 / 55 /
20
/
34
)
WNT signaling ( 396 / 199 /
88
/
109
)
anchorage-independent growth ( 37 / 19 /
10
/
8
)
Bone metastasis ( 26 / 15 /
3
/
8
)
Castrate Resistance ( 27 / 16 /
9
/
2
)
Hedgehog (Hh) signaling ( 32 / 17 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
Adriamycin (Adr) resistance ( 30 / 16 /
4
/
10
)
aerobic glycolysis ( 83 / 42 /
12
/
29
)
docetaxel resistance ( 47 / 25 /
16
/
6
)
epirubicin resistance ( 5 / 3 /
2
/
)
gefitinib resistance ( 38 / 20 /
6
/
12
)
JAK/STAT signaling ( 116 / 59 /
31
/
26
)
mTOR signaling ( 92 / 46 /
12
/
34
)
Necrosis ( 6 / 3 /
2
/
1
)
NOTCH signaling ( 91 / 46 /
23
/
22
)
P38 signaling ( 33 / 17 /
10
/
6
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
unfolded protein response ( 7 / 5 /
1
/
1
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
lipogenesis ( 25 / 13 /
1
/
11
)
TGF-beta signaling ( 454 / 252 /
103
/
99
)
Temozolomide (TMZ) resistance ( 38 / 19 /
6
/
13
)
BMP signaling ( 233 / 126 /
72
/
35
)
Lapatinib resistance ( 6 / 3 /
1
/
2
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
gemcitabine resistance ( 58 / 29 /
9
/
20
)
genomic instability ( 4 / 2 /
1
/
1
)
Sorafenib resistance ( 40 / 20 /
6
/
14
)
glucose metabolism ( 18 / 9 /
3
/
6
)
BRCAness ( 2 / 1 /
1
/
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 26 / 13 /
7
/
6
)
Hippo signaling pathway ( 178 / 89 /
66
/
23
)
fibrosis ( 42 / 21 /
8
/
13
)
MAPK/JNK Signaling Pathway ( 22 / 11 /
5
/
6
)
carboplatin resistance ( 4 / 2 /
1
/
1
)
Hypoxic response ( 10 / 6 /
4
/
)
Taxanes (paclitaxel and docetaxel) resistance ( 20 / 13 /
4
/
3
)
Trastuzumab resistance ( 16 / 8 /
5
/
3
)
TRAIL resistance ( 16 / 8 /
5
/
3
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
pyroptosis ( 16 / 8 /
7
/
1
)
Sunitinib resistance ( 8 / 4 /
4
/
)
IFN production ( 10 / 5 /
2
/
3
)
Antiviral response ( 11 / 6 /
2
/
3
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 32 / 17 /
/
15
)
cell spreading ( 8 / 6 /
/
2
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Imatinib resistance ( 18 / 11 /
/
7
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
Camptothecin resistance ( 3 / 2 /
/
1
)
disease-free survival ( 3 / 2 /
/
1
)
EGFR-TKI resistance ( 4 / 3 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
gluconeogenesis ( 4 / 2 /
/
2
)
Afatinib resistance ( 2 / 1 /
/
1
)
Neratinib resistance ( 2 / 1 /
/
1
)
Brain metastasis ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
BCL2 inhibitors resistance ( 2 / 1 /
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
glycolysis ( 13 / 13 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Response to oxidative stress ( 12 / 12 /
0
/
0
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Tyrosine kinase inhibitors (TKIs) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)